Drugmaker announces immuno-oncology startup with New Zealand university

BioMotiv, a Cleveland-based drug development accelerator associated with The Harrington Project, and a university in New Zealand have announced the formation of an immuno-oncology startup that will develop a suite of cancer vaccines.

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us